HQP1351 is a 3rd generation BCR-ABL/KIT inhibitor targeting BCR-ABL mutants, including those with the T315I mutation. We are developing HQP1351 as a monotherapy for the treatment of resistant CML and GIST. A Phase I clinical trial in patients with resistant CML has been completed in China. Preliminary data showed that HQP1351 achieved significant antitumor activity in drug resistant CML patients with a favorable safety profile. With the encouraging clinical data, we initiated a potential pivotal Phase II trial in patients with resistant CML in China. We also plan to file an IND for a Phase II trial in the U.S. for CML. In addition, we have initiated a Phase I trial in patients with GIST in China.